The study found that TFDC might inhibit the inflammatory response in treating gout by regulating the arachidonic acid metabolic pathway, especially its active compound apigenin could significantly inhibit the related targets of prostaglandin G/H synthase 2 (PTGS2), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in this pathway [9]. Here, PTGS2 is linked to gout.